Trial Profile
A Non-randomized Trial to Evaluate a TEst and Treat Intervention Integrating Novel Point-of-care Hepatitis C RNA Testing, Linkage to Nursing Care, and Peer-supported Delivery of HCV Testing and Treatment aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TEMPO
- 13 Jan 2023 Status changed from recruiting to completed.
- 19 Aug 2022 Planned End Date changed from 1 Mar 2022 to 1 Dec 2023.
- 19 Aug 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Dec 2022.